Spectral Medical ( TSE:EDT ) Third Quarter 2024 Results Key Financial Results Revenue: CA$502.0k (up 26% from 3Q 2023...
Spectral aims to finalise enrolment in early 2025 for its septic shock treatment Toraymyxin.